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Abstract: 
The widely accepted paradigm that epoxidized methyl farnesoates (“juvenile hormones,” JHs) 
are the principal sesquiterpenoid hormones regulating insect metamorphosis was assessed 
in Drosophila melanogaster. GC–MS analysis of circulating methyl farnesoids during the mid to 
late 3rd instar showed that methyl farnesoate is predominant over methyl epoxyfarnesoate (=JH 
III). The circulating concentration of methyl farnesoate (reaching nearly 500 nM), was easily 
high enough on a kinetic basis to load the Drosophilaortholog of the nuclear hormone 
receptor RXR (also known as “ultraspiracle,” USP), whereas the circulating concentrations of JH 
III and methyl bisepoxyfarnesoate (bisepoxyJH III) were not. The hypothesis that the ligand 
pocket of USP necessarily binds an endogenous ligand for differentiation of the immature to the 
adult was tested with USP mutated at residue that normally extends a side chain into the ligand 
binding pocket. An equilibrium binding assay confirmed that the mutation (Q288A) strongly 
altered methyl farnesoate interaction with USP, while a heterologous cell-line transfection assay 
confirmed that the mutation did not allosterically alter the transcriptional response of the 
ultraspiracle/ecdysone receptor heterodimer to ecdysteroid signaling. Transgenic wildtype USP 
driven by the cognate natural promoter rescued null animals to develop to the adult inside a 
normally formed puparium, while in contrast animals transgenically expressing instead the 
ligand pocket mutant exhibited developmental derangement at the larval to pupal transition, 
including failure to form a properly shaped or sclerotized puparium. Other point mutations to the 
pocket strongly reducing affinity for methyl farnesoate similarly disrupted the larval to pupal 
metamorphosis. These results suggest that normal larval to pupal maturation in this mecopteran 
model insect requires the involvement of a distinct endocrine axis of USP binding to its own 
endogenous terpenoid ligand. 
Abbreviations 
JH, juvenile hormone; USP, ultraspiracle; EcR, ecdysone receptor; 20E, 20-OH ecdysone; RXR, 
retinoid X receptor 
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Article: 
1. Introduction 
An important nuclear hormone receptor that is necessary for cell differentiation in both 
vertebrates and invertebrates is the retinoid-X-receptor (RXR; known as “ultraspiracle” or USP 
in higher insects). RXR or USP is an obligate heterodimer partner for many other nuclear 
hormone receptors (e.g., for the farnesoid X receptor in vertebrates and for the ecdysone receptor 
(EcR) in invertebrates [15], [22] and [37]). 
There is uncertainty on whether a nanomolar affinity endogenous ligand exists for RXR in either 
the vertebrates or invertebrates [9], [44], [63] and [69]. In some invertebrates, studies using different 
methods report various outcomes as to whether RXR binds 9-cis RA with high affinity or can be 
transcriptionally activated by 9-cis RA [7], [40] and [68]. While some insect RXRs are reported not to 
bind or not to be transcriptionally activated by 9-cis RA [5] and [28], in contrast is the report of the 
nanomolar affinity of retinoic acid for locust RXR [45]. 
Our recent data suggest that a nanomolar affinity sesquiterpenoid ligand exists for mecopteran 
RXR (USP). Of the compounds biosynthesized in culture by ring glands of Drosophila 
melanogaster (hereafter,Drosophila), two are unique to insects in the animal kingdom (methyl 
epoxyfarnesoate = JH III, and methyl bisepoxyfarnesoate = bisepoxyJH III), while the third, 
methyl farnesoate, is a circulating compound in Crustacea [30] and [41]. In an equilibrium binding 
assay screen of natural products of the insect farnesoid biosynthesis pathway, the insect farnesoid 
with strongest affinity for Drosophila USP was methyl farnesoate (Kd = 40 nM [34]), similar to 
the affinity of vertebrate RXR for 9-cis RA [11]. In addition, in some synthetic reporter contexts, 
methyl farnesoate potentiates the transcriptional response of the RXR or USP heterodimer 
partner, the ecdysone receptor (EcR), to its own ligand, 20-OH ecdysone (20E; [4] and [66], 
consistent with the hypothesis that the USP ligand binding pocket has a structural capacity to 
respond to an intrinsic ligand. In contrast, while JH III can be made to load USP at micromolar 
concentration [34],[35] and [36] and also at that concentration enhance 20E-induced reporter 
activity [18], JH III has been recently reported to have low nanomolar affinity instead for the germ 
cell expressed (GCE) protein and perhaps the methoprene tolerant (MET) protein [6] and [10]. 
However, there have not yet been reports providing a functional demonstration that the RXR or 
USP molecule requires a ligand binding capability to its ligand pocket in order to function in 
vivo. Nor has a measured circulating titer of methyl farnesoate been reported in insects that is at a 
level corresponding to theKd of the cognate species’ RXR or USP. Hence, in the present study, 
we have directly addressed these issues. We demonstrate that methyl farnesoate circulates 
in Drosophila at a level that corresponds favorably to its Kd for USP, and that USP ligand pocket 
debilitated for methyl farnesoate binding cannot sustain normal larval development through 
metamorphosis to the pupa. 
2. Materials and methods 
2.1. Physiochemical detection of circulating methyl farnesoids 
The methods used here are the procedures for GC–MS–CI after micro-solid phase extraction, 
described previously for the determination of circulating methyl farnesoids in D. 
melanogaster [31] and [33]. 
2.2. Mutagenesis of ligand binding pocket residues 
We identified a specific USP amino acid residue, Q288, with a side chain (a) that points into 
the DrosophilaUSP (dUSP) ligand binding pocket [12] and [57], (b) that also contacts terpenoid 
ligand in the respective vertebrate and mollusk RXR/ligand complexes [17] and [20], and (c) which 
was unlikely to be involved in allosteric effects to disrupt DNA binding, or heterodimerization 
with EcR, or ligand binding by EcR. For example, mutation of hRXR residue Q275 (=dUSP 
Q288) decreased transcriptional activation by 9-cis RA [56] and [73], but did not affect 
heterodimerization [56]. By a similar approach, we also mutated to alanine a residue at the deep 
end of the pocket (N325) that has been modeled as potentially interacting with the methyl ester 
of a terpenoid ligand [56], and that does not make contact with a phospholipid that occludes the 
pocket opening in crystal structure preparations [12] and [57]. 
The CaSpeR-based pMVZ15 vector [26] for transgenic expression of a wild type or mutant USP 
gene (mutation confirmed by sequencing) was used to prepare fly lines reported here. When the 
wild type USP coding sequence is driven by the natural USP promoter in this construct, in a null 
(usp2) background, it can rescue larval development to the adult [26]. 
2.3. Ligand binding assay 
We used an equilibrium binding assay, based on quenching of intrinsic receptor fluorescence, 
that has been widely used in the field of vertebrate nuclear hormone receptors to evaluate ligand 
affinity, e.g., RXR [11], farnesoid X-receptor (FXR, [23]), androgen receptor (AR, [29]), hepatocyte 
nuclear factor (HNF, [48]), peroxisome proliferator activated receptor (PPAR, [58]), and vitamin 
D3 receptor (VDR, [61]), and to study ligand binding by other kinds of proteins (see Ref. in [70]). 
Advantages of this approach are that not only does it provide a means to measure ligand affinity 
(i.e., Kd), but the differential effect of alternative ligands on the conformation of the receptor can 
possibly be also detected by the nature of the fluorescent response. E.g., the change in 
fluorescence report of the receptor population under saturating conditions may be a net 
fluorescence suppression for one ligand, little net change for another ligand, or an increase for 
another. When the ligands themselves do not absorb at the fluorescing wavelength of the 
receptor (as is the case with methyl farnesoids), differences in final changes in fluorescence of 
the receptor indicate differences in conformation of the receptor (differences in local tryptophan 
environments) induced upon binding of the respective ligand (discussed previously in further 
detail by [34] and [70]). There is the additional utility that a ligand which upon binding causes a 
receptor conformation that imparts little or no net change in fluorescence can still be kinetically 
measured as binding to the receptor by its concentration-dependent, competitive displacement of 
a ligand that does cause a strong net fluorescence change. For example, farnesol and JH acid, 
which do not themselves cause much net change in receptor fluorescence at their respective (very 
high) saturation concentrations, can by mass action at a sufficiently excess concentration finally 
displace the much higher affinity and more strongly fluorescence-suppressing methyl 
farnesoate [34] and [70]. The particular range of concentrations of the respective ligand that leads up 
to its saturation of the receptor population, measured either directly or by competitive 
displacement, then yields by conventional bimolecular binding analyses [62] the calculation of the 
respective affinity constant. For example, two compounds, such as methyl farnesoate and JH III, 
that cause different final protein conformations at their respective saturating concentrations [70], 
may at those respective saturation concentrations cause similar final net suppression of USP 
fluorescence [35], but their very different affinity for USP is shown by the very different range in 
respective concentration (nanomolar for MF; micromolar for JH III) over which the binding 
curve leads to saturation [34]. 
Recombinant wild type and mutant USP were bacterially expressed, and purified over, first, a 
nickel resin column and, second, a Superdex 200 size exclusion column, similar to that described 
previously [34], Fig. S1). Purified receptor was adjusted to 0.7–1 μM, allowed to equilibrate 
overnight, and then subjected to a fluorescence-based ligand binding assay as described 
previously [34]. In this assay, the receptor itself is stable, and its binding of ligand is measured by 
a change in fluorescence to a new stabilized level (Fig. S2). Because the concentration of 
receptor that was used either approached or was higher than the Kd for the tested ligand, the 
kinetic binding curves were analyzed by a nonlinear method [62]. Three independent preparations 
each of wild type and mutant receptor were used to estimate the Kd of the ligand methyl 
farnesoate (Echelon Inc.) for each receptor type. For certain controls, juvenile hormone III 
(prepared by P. Teal) or tributyltin (Sigma–Aldrich) were also used. The latter, an environmental 
endocrine disrupter [21], has been demonstrated to physically bind to both vertebrate and 
invertebrate RXR, and has been co-crystalized with RXR [43], in a near covalent association with 
a ligand pocket cysteine residue [43] that is conserved in Drosophila USP (C472). 
2.4. Intracellular reporter assay of receptor function 
The Chinese hamster ovary (CHO) cell transfection functional assay for response to ecdysteroid 
signaling, described previously [4] and [25], was used to assess the performance of wild type USP 
and Q288A mutant USP as the heterodimeric partner of the Drosophila ecdysone receptor (EcR). 
Cells were cotransfected with plasmids expressing each receptor under a constitutive actin 
promoter. Also cotransfected was a transcription reporter plasmid expressing firefly luciferase, 
and containing five copies of a USP/EcR heterodimer binding site. Finally, also cotransfected 
was a control reporter plasmid, constitutively expressing a different reporter, used for 
normalization. 
2.5. D. melanogaster handling and transgenic lines 
Wild type (yw) larvae were reared at 25 °C on standard diet and hemolymph collected as 
described elsewhere [31] and [33]. 
Wild type (w1118) transgenic lines expressing transgenic wild type or mutant ultraspiracle in 
the w1118 wild type background were prepared by Rainbow Transgenic Flies Inc., Newberry Park, 
CA. Multiple independent lines were prepared and tested for each USP construct. For tests that 
challenged the particular form of USP to perform in a null (usp2) background, females of the null 
line [usp2/FM7i, P{ActGFP}JMR3] were crossed with males homozygous on either chromosome 
2 or 3 for the test USP (the FM7 balancer, that is marked with bar has a wild type usp allele). 
The male usp2 (i.e., null) progeny could be identified from the FM7 progeny by the lack of the 
GFP marker, and from usp2/+ female progeny by the testes (late 3rd instar larvae) and in the 
adult by the forked marker on the usp2 chromosome. 
2.6. qPCR analysis of expression of selected genes 
Null usp2 larvae expressing transgenic Q288A L366A mutant USP identified as exhibiting stages 
of wandering behavior (‘can walk slowly,’ ‘can barely walk,’ ‘can sway and writhe but not 
walk’; four larvae per stage) were homogenized in Trizol reagent. Sibling normal larvae in 
comparable stages (‘can walk slowly,’ ‘can sway and writhe,’ ‘can sway with anterior spiracle 
beginning to protrude’; four larvae per stage) were similarly collected. The ‘can walk slowly’ 
stage is at the very end of gut clearance as assessed by inclusion of bromophenol blue in the 
food. The Trizol extracts were processed through chloroform, isopropanol precipitation, 70% 
EtOH washing, and then resuspended in DEPC-treated water. RNA concentrations were 
quantified and purity assessed by Nanodrop. Trace genomic DNA was digested using Ambion’s 
Turbo DNA-free kit and accompanying protocol. RNA was reverse transcribed using 
Invitrogen’s SuperScript III kit, oligo dT, and accompanying protocol. cDNA samples were 
appropriately diluted to be used in fluorescein-normalized/SYBR green-detected RT PCR assays 
using Fermentas’ Maxima reagent and BioRad’s iCycler system. Primers were designed to have 
a 20 bp length, 60 °C Tm, and 70–150 bp product size. Duplicate 25 μl reactions using 5 μl of 
diluted cDNA were used to quantify transcript for each sample. 
No-template controls were used to assess spurious amplification or aberrant primer activity and 
melt curves were performed to assess product specificity. Data were normalized to expression of 
the indicated ribosomal protein gene. 
3. Results 
3.1. Physiochemical detection of circulating methyl farnesoids 
Using our previously established GC–MS–CI methods [31] and [33], we carefully examined the 
hemolymph for the presence of three methyl farnesoids previously shown to be secreted in 
culture by the larvalDrosophila ring gland [50]. During the period from the mid-3rd larval instar 
to puparium formation (that encompasses the start of larval to pupal metamorphosis), methyl 
farnesoate, JH III, and bisepoxyJH III were all physiochemically established to be present ( Fig. 
1). Example chromatograms for the single ion monitoring used to detect and quantify the 
amounts of the three methyl farnesoids in samples are shown in Fig. S3. 
 
Fig. 1. GC–mass spectrometry analysis of the three natural methyl farnesoates isolated from the 
hemolymph of 3rd instar feeding stage of Drosophila melanogaster. Panels A–C show the 
fragments obtained from synthetic and natural methyl epoxyfarnesoate (JH III, juvenile hormone 
III), methyl farnesoate (MF) and methyl bisepoxyfarnesoate (bisJHIII). 
3.2. Concentrations of circulating methyl farnesoids 
In confirmation with previous reports of the presence of JH III in whole body extracts 
of Drosophila [8] and [59], an increase in the circulating JH III titer during the wandering stage was 
observed (up to ca. 100 nM) followed by a decline toward pupariation ( Fig. 2). However, at all 
the time points sampled, methyl farnesoate was present in greater concentration than JH III 
(t, p < 0.05), ranging from 75 to 500 nM, and up to 50 times the concentration of classical JH III. 
BisepoxyJH III was significantly lower than methyl farnesoate at both wandering and puparium 
formation (t, p < 0.05), However, both were similar during last 24 h of the feeding period. 
 
Fig. 2. Titer of circulating methyl farnesoids in Drosophila melanogaster during the 3rd larva 
instar prior to the onset of metamorphosis. At each stage, methyl farnesoate is the hormone in 
dominant concentration in the hemolymph. Values shown are the mean ± SEM of at least three 
independent samples, of at least 10 animals each. 
The nuclear concentration in various tissues of most lipophilic hormones that bind vertebrate or 
invertebrate nuclear hormone receptors is unknown. Hence, inferences that specific hormones 
(e.g., 20E, JH III or methyl farnesoate) are binding intranuclearly with the respective receptors at 
particular developmental times is necessarily tentative. However, we noted that even if the 
nuclear concentration of methyl farnesoate is one tenth that of the circulating titer reached in Fig. 
2, it would still be at the physical Kd of methyl farnesoate for USP [34], while in contrast, even if 
the nuclear concentration of either JH III or bisepoxyJH III were 10 times the circulating 
concentration shown in Fig. 2, it would still be at least 5–10 times lower than their 
respective Kd for USP [34]. These titer and binding affinity data further prompted our 
experimental consideration of whether the ligand binding pocket of USP is functionally 
necessary for successful larval to pupal metamorphosis. 
3.3. Functional necessity of USP ligand binding pocket 
Developing animals that are null for usp die at the first larval molt [47]. These null larvae are 
rescued to develop to the adult stage by transgenic insertion of a wild type usp that is under the 
control of a natural usp promoter [26]. Using this functional rescue assay, we tested whether the 
wild type function of specifically the ligand binding pocket of USP is necessary for larval–pupal 
metamorphosis. 
3.4. High affinity equilibrium binding of methyl farnesoate 
First, we reconfirmed the physical affinity of the ligand binding pocket of Drosophila USP for 
methyl farnesoate, using a fluorescence equilibrium binding assay that has been well established 
for a wide variety of nuclear hormone receptors. As shown in Fig. 3A, methyl farnesoate binding 
to USP (1) distinctly suppresses fluorescence of the receptor, (2) exhibits saturable binding 
kinetics, and (3) yields a Kd of ca. 40 nM (similar to the specific binding of 9-cis retinoic acid to 
vertebrate RXR), as we previously reported [34]. The equilibrium interaction of methyl farnesoate 
with the ligand binding pocket was confirmed by a competition assay using tributyltin (TBT), a 
ligand that forms a semi-covalent bond with a highly conserved cysteine residue near the 
opening of the ligand pocket of vertebrate RXR (residue C372 in Drosophila USP). Such 
properties confer to TBT the kinetic behavior of a ‘slow, tight-binding’ ligand. This cysteine 
residue to which TBT binds is on the opposite side of the ligand binding pocket from the 
fluorescent tryptophan residue W318 ( Fig. S4B) that inserts its indole side chain into the pocket. 
The binding of TBT to USP hence has little effect on fluorescence of the receptor ( Fig. 3B). 
However, when both the high-affinity, but equilibrium ligand methyl farnesoate and the slow, 
tight binding TBT are added together, the fluorescence is initially suppressed by the rapidly 
binding methyl farnesoate ( Fig. 3B, inset). Then, as would be predicted by equilibrium kinetics, 
the equilibrium-binding ligand methyl farnesoate is slowly displaced from the USP pocket by the 
semi-covalent binding by TBT, so that finally the fluorescence of the USP protein is similar to 
that observed in the presence of TBT alone, i.e., little suppression ( Fig. 3B, inset). These 
kinetics exhibit the properties that would be predicted by (1) the high affinity, equilibrium 
binding of methyl farnesoate to the established ligand pocket of USP, and (2) its competitive 
displacement from the ligand pocket by the established pocket ligand, TBT. These results 
confirm that Drosophila USP has a ligand pocket that is structurally competent to bind ligand. 
 
Fig. 3. Binding of methyl farnesoate to purified, recombinant wild type and mutant (Q288A) 
USP. (A) Panels at right show example preparations of purified wild type (above) and mutant 
(below) USP, following SDS–PAGE. At left, saturation equilibrium binding curves of methyl 
farnesoate with wild type (above) and mutant (below) USP. The average ± SEM Kd of methyl 
farnesoate calculated for wild type USP was 39 ± 31 nM, while the affinity constant calculated 
for Q288A USP was significantly reduced, 173 ± 42 nM (p < 0.05; n = 3 each). The % 
suppression of receptor fluorescence for wild type USP at saturating ligand concentration was 
14.7% ± 1.3. (B) Tributyltin (TBT), is an established RXR ligand [21] and [63] that forms a near 
covalent association with a conserved cysteine (C472) in the ligand pocket [40]; this residue is 
on the other side of the pocket from the fluorescing tryptophan (W305) and TBT binding has 
little net effect on receptor fluorescence. In a concentration dependent manner, TBT displaces 
the fluorescence-suppressing methyl farnesoate from the ligand binding pocket. As predicted for 
a slow, tight-binding ligand, TBT in a time course slowly displaces the higher affinity, 
fluorescence-suppressing methyl farnesoate from the ligand binding pocket (inset). 
3.5. Mutational weakening of methyl farnesoate binding (Q288A) 
In the human RXRα-ligand crystal structure, the glutamine residue Q275 interacts with one of 
the two carboxylate oxygens of 9-cis RA [17]; Fig. S4A). This residue is conserved 
in Drosophila USP as Q288 ( Fig. S4B). When the residue Q288 was mutated to alanine, 
the Kd for methyl farnesoate was reduced (Kd = 170 nM, p < 0.05; Fig. 3A). We considered 
previous reports that some point mutations to vertebrate RXR binding pocket can cause both 
reduced affinity to normal ligand and increased affinity to a nonnormal ligand [16], and that 
whereas wild type Aedes aegypti EcR is activated by both ecdysone and 20E (which differ by a 
single hydroxyl), a particular pocket point mutation dramatically changes affinity for ecdysone 
but not for 20E [65]. In the present study, we found that the micromolar affinity of USP to JH 
III [34] was not changed by the Q288 mutation ( Fig. S5). Hence, misfunction of the USP ligand 
pocket due to mutation of Q288A is not likely to be due to ‘new’ nanomolar affinity binding to 
JH III. 
3.6. Q288A USP mutation does not allosterically disrupt EcR performance 
USP has been shown to function as an indispensible heterodimer partner of EcR in the nuclear 
transduction of ecdysteroid signaling [22] and [72]. We functionally confirmed that the Q288A 
mutation does not have an allosteric effect on the ability of the USP heterodimer partner, the 
ecdysone receptor (EcR), to transduce ecdysteroid signaling into a transcriptional response. In 
CHO cells treated with a physiological level of the ecdysone analog muristerone, the 
heterologously coexpressed wild type EcR/USP transduced the transcriptional report of a target 
plasmid containing an EcR/USP heterodimer binding site (Fig. 4; [25]). The same level of 
transcriptional report, as was seen with the presence of the wild type USP, was obtained when 
instead the mutant Q288A was used (Fig. 4, p > 0.05). The similar transcription report in the 
presence of the mutant USP ligand pocket as compared to the wild type USP was also observed 
when either the EcR isoform B1 or B2 was cotransfected. 
 
Fig. 4. CHO cell transfection assay of the response of USP/EcR heterodimer to 100 nM 
muristerone A (the approximate concentration 20-OH ecdysone prior to pupariation [67]). Cells 
were cotransfected with plasmids expressing USP and EcR, as well as a reporter plasmid 
containing five tandem USP/EcR heterodimer binding sites, and a constitutively expressed 
reporter used for normalization. As indicated, cells were transfected with plasmid expressing 
EcR isoforms B1 or B2, each of which was paired with either wild type USP or the Q288A 
mutant USP. For every combination, the responsiveness of the heterodimer to the muristerone A 
was the same (p > 0.05), showing that the Q288A mutation did not allosterically affect the ability 
of the heterodimers to respond to ecdysteroid signaling. Values are average ± SEM, three 
independent replications each. 
3.7. Q288A mutant cannot perform as wild type USP in vivo 
The Q288A mutant USP was then challenged to functionally replace the missing wild type USP 
in the nullDrosophila background. In Drosophila, development through the first two larval molts 
is driven by pulses of 20E that are widely understood to be transduced by 20E binding to the EcR 
partner of the USP/EcR heterodimer [51]. Null usp larvae, containing only transgenic Q288A USP 
(i.e., no wild type USP), progressed through the first two larval molts in synchrony with siblings 
that instead possess an endogenous wild type USP (confirmed in multiple independent lines). 
This result confirms that the Q288A mutation to USP does not in and of itself allosterically 
prevent the USP/EcR heterodimer from transducing 20E signalingin vivo (this result is 
concordant with the above CHO cell transfection results). Once the Q288A larvae attained the 
metamorphic 3rd instar (with a briefly longer 3rd instar feeding stage compared to normal 
larvae), larvae stopped feeding, came to the surface of the food, exhibited wandering behavior 
and then became quiescent, these all being normal stages signaling the onset of 
metamorphosis [52]. The larvae then exhibited apolysis of the epidermis away from the cuticle, to 
form the body of the cryptocephalic pupa ([2];Fig. 5, arrows), again as occurs in the normal 
metamorphic larval to pupal metamorphic process. However, most larvae did not form a normal 
puparium, i.e., did not form a structure that was barrel-shaped (with anterior spiracles everted at 
an angle), hardened (sclerotized), and brown (tanned). Rather, the puparium was dorso-ventrally 
flattened, the partially everted anterior spiracles pointed directly forward, the cuticle only faintly 
sclerotized, and the ‘puparial’ cuticle transparent rather than brown ( Fig. 5). Most animals 
stopped development during the early pupal stage, and eventually died after dessication (though 
in some animals the compound eyes of the cryptocephalic head partially pigmented). 
 
Fig. 5. Transgenic USP mutated for decreased ligand binding cannot sustain normal development 
through metamorphosis by null (usp2) animals. Above left two panels are wild type pupa and 
pharate adult stages. Above right two panels, mutant Q288A animals that developmentally 
arrested shortly after apolysis to the pupa (shown by retraction of the abdomen from the 
abnormally formed puparium, arrows), with incomplete head eversion. This was the predominant 
phenotype observed. Shown below are data for two independent transgenic USP fly lines each. 
When males of the given line are crossed to females that are heterozygous on chromosome 1 
as usp2/FM7i, P{ActGFP}JMR3, one fourth of the resulting progeny are expected to be male 
larvae that are null for endogenous usp, but which possess a single copy of the test transgenic 
‘rescue’ usp. 
3.8. Additional ligand pocket mutants cannot perform as wild type USP in vivo 
We examined the effect on ligand binding and in vivo performance two more mutant USPs: (1) a 
double mutant (Q288A L366A; the L366 residue is highly conserved in vertebrate and 
invertebrate RXR, and contacts the carboxyl group of 9-cis RA [17] and [57]), and (2) the mutant 
N325A (this residue, that is at the deep end of the pocket, has been modeled as potentially 
interacting with the methyl farnesoid carboxyl group[57]; Fig. S4B and S4C)). Both mutant USPs 
possessed a significantly reduced affinity for methyl farnesoate (Q288A 
L366A, Kd = 1.3 ± 0.14 μM; t, p < 0.05; N325A, Kd = 2.3 ± 0.72 μM; t, p < 0.05). Both mutant 
receptors were able to sustain development through the 20E-driven first and second larval molts, 
supporting that the mutations to USP did not allosterically cause the EcR heterodimer partner to 
be unable to respond to 20E-signaling. However, neither the Q288A L365A nor the N325A 
mutant USP were able to sustain null usp larval development through the larval to pupal 
transformation. For both, most larvae ceased feeding and came to the surface of the food, 
exhibited wandering behavior, became quiescent, and apolysed to the cryptocephalic pupal body 
( Fig. 6, arrows). However, most of the morphogenetic events of puparium formation were 
omitted by the Q288A L366A and N325A animals. The anterior spiracles did not evert to their 
full extension or proper angle; the cuticle did not become barrel-shaped, and remained soft and 
did not tan. These animals were never seen to exhibit pigmentation in the cryptocephalic eyes, 
prior to their desiccation and death within a day or two. 
 
Fig. 6. Development of null usp male larvae cannot be sustained past the larval–pupal 
transformation by expression of either a transgenic N325A mutant or a Q288A L366A mutant 
USP. Shown in the upper panels of (A) and (B) is the respective predominant phenotype 
observed (arrows show area of apolysis). The independent lines for each were generated by the 
methods described for Fig. 5. The data shown below the photographs in (A) and (B) confirm that 
neither USP mutant was functionally capable of sustaining normal development in the 
null usp males (i.e., no null males were rescued to attain puparium formation). By comparison, 
all null males were rescued to form a normal puparium by provision of a wild type usp transgene 
(as reported previously [22]). The lower panels of (A) and (B) show respective physical binding 
curves of methyl farnesoate to a preparation of purified N325A or Q288A L366A mutant USP. 
The calculated Kd is for the respective mutant USP is shown with each curve (avg ± SEM; n = 3 
each). For each mutant USP, the Kd is significantly lower than the Kd for wild type USP ( Fig. 3) 
(p < 0.01). Inset: qPCR analysis of mRNA levels for USP, EcR and dopa decarboxylase (DDC), 
during 3rd instar wandering stages (normalized to RP49), of null (usp2) larvae expressing a 
transgenic mutant USP (Q288A L366A), and of normal siblings. There is no significant 
difference in relative levels (y-axis) of mRNA for USP or EcR (p > 0.05); however the level of 
DDC expression in null larvae expressing the mutant USP is significantly lower than that of 
normal larvae (p < 0.05). 
qPCR analysis of Q288A L366A animals confirmed that during the period on the food prior to 
becoming motionless, the levels of expression of (the transgenic) USP and of the endogenous 
EcR isoform B1 in nullusp larvae were not significantly different from normal sibling larvae 
( Fig. 6B, inset graph; t, p > 0.05). Relevantly, the level of expression of dopa decarboxylase 
(necessary for puparium hardening [71]) was significantly lower than in normal larvae ( Fig. 6B, 
inset graph, t, p < 0.05). Analysis of the expression of a cuticle-specific protein gene that is 
specific for the pupal stage, Edg84, showed that the gene is not significantly expressed during 
the first several hours after puparium formation in normal larvae, or at the corresponding stage 
(by time post quiescence) of Q288A L366A larvae. However, for both the normal animals and 
correspondingly staged (by time) double mutant animals, Edg84 becomes highly expressed in the 
several hours after pupal head eversion (>100×, about fivefold lower in the mutant larvae). 
Hence, the mutant USP animals have not simply arrested at a larval stage prior to the onset of 
metamorphosis; rather, specifically the formation of a normal puparium was not exhibited as the 
animal proceeded to a larval-to-pupal metamorphic program. 
4. Discussion 
4.1. Physical measurement of circulating methyl farnesoids 
Until recently, physiochemical methods have suffered from a lack of sensitivity due to 
instrument limitations, which required large amounts of sample [8], [19] and [59]. However, advances 
in instrumentation over the past decade have resulted in both increases in sensitivity and 
reductions in signal to noise ratios (Fig. S3), which have reduced by orders of magnitude the 
amounts of analytes needed [64]. Thus, using the techniques we employed in this work, we were 
routinely able to effectively analyze and quantify samples containing as little as 2 nM of the 
given methyl farnesoid. 
Although previous studies have reported that methyl farnesoate, JH III and JH III bisepoxide are 
released by cultured dipteran ring glands [50], there are no reports thus far the use of 
physicochemical approaches to detect methyl farnesoate in Drosophila larvae. (JH III has been 
reported from Drosophila whole body extracts [8] and [59]. It is crucial to identify the major methyl 
farnesoids that are in circulation following secretion by the ring gland, so as to enable defining 
their respective metamorphic roles [14] and [53]. Here, we have determined that all three methyl 
farnesoids are in larval circulation, with methyl farnesoate (reaching several hundred nanomolar) 
being more abundant than JH III at all sampled stages, and being the most abundant of all three 
at wandering and white puparium stages. However, the 3rd feeding stage period sampled across 
(12–36 h into the 3rd instar), is a long period during which time there could be differing changes 
in the concentrations of the three hormones. 
4.2. Implications for functionally circulating methyl farnesoids 
The ‘classical model’ of endocrine coordination of metamorphic transformation of insect cells 
specifies the interaction of two lipophillic ligands with their respective receptors: the steroid 20E 
and the terpenoid JH III. It is well established that the ecdysone receptor (EcR) is required in 
transducing 20E signaling, and there is increasing evidence that JH III signaling is transduced in 
insects through a MET paralog (GCE), or in Drosophila, both GCE and MET (both being 
bHLH-PAS transcription factors [3] and [38]. 
However, this 2-axis model (20E/EcR and JH/GCE(MET)) for metamorphic development 
appears incomplete. We have shown here that methyl farnesoate exists in circulation in 
significantly higher concentration than JH III. In addition to the 100× greater affinity of USP for 
methyl farnesoate than JH III[34], two independent recent studies have observed exogenous 
methyl farnesoate to be as active or more active than JH III in exerting some biological activities 
prior to pupariation [24] and [33]. These circumstances warrant the consideration of an alternative 
model in which methyl farnesoate is a bona fide circulating hormone contributing to the 
regulation of Drosophila larval development. 
4.3. Implications for functional RXR/USP and ligand integration 
The evolution of RXR and USP in the invertebrates in relation to ligand binding is an active area 
of in silicoanalysis. Attempts have been made to relate functional significance to patterns of 
evolutionary change in ligand binding residues to crystallographic structures or mass 
spectrometric fragments of the ligand binding domain, when it is expressed in isolation of the 
remainder of the receptor protein sequence. Interpretations have been complicated by what the 
investigators characterize as “fortuitous” insertion of various phospholipids at the opening of the 
ligand binding pocket under conditions necessary for crystallization or mass 
spectrometry [12] and [49], including that phospholipid becomes inserted in a manner that 
distortionally widens that opening of the pocket [60]. Recently, Hult et al. [27] performed a 
computational analysis that led the authors to confirm positively-selected evolutionary change in 
the ligand binding domain of dipteran and other mecopteran USP, and agreed that phospholipid 
is not the natural endogenous ligand. Those authors urged that site-directed mutagenesis be 
conducted in order to better understand the physiological implications of the evolution of 
mecopteran USP. 
In previous studies using a chimeric GAL4-USP ligand binding domain and a synthetic UAS 
reporter promoter, several researchers did not detect a direct activation response of the chimeric 
USP construct to methyl farnesoids in transgenic fly larvae [5], [39] and [46]. However, in a cell 
culture transfection system a similarly constructed USP ligand binding domain transduced 
potentiation of 20E activation of the ecdysone receptor, by either methyl farnesoate or JH III [4], 
consistent with the hypothesis that the USP ligand pocket has the structural capacity to bind and 
respond to an intrinsic ligand. In a transfection assay, an intact mollusc RXR shown to bind 9-
cis retinoic acid did not activate transcription of a synthetic reporter from a heterologous RXR 
binding site [7]. Yet, transcriptional activation was observed in a cell transfection system that 
utilized full length USP, a natural Drosophila USP binding site (DR12), micromolar 
concentrations of an epoxidized analog of methyl farnesoate (i.e. JH III), and a JH-sensitive 
promoter from a lepidopteran species that also possesses a USP form of RXR [18], again 
consistent with Drosophila USP possessing a structurally competent ligand binding pocket. 
Recently, Jones et al. [32] have shown that in cell transfection reporter assays, selection of the 
appropriate reporter core promoter is crucial: even closely related core promoters have vastly 
different response (or none) to JH and trimming even a small region of natural sequence 5′ to the 
core promoter can greatly alter the level and even direction of reporting behavior. Hence, we 
consider that the differences in outcomes of the above reporter-based studies may have arisen 
from the presumptions as to how ligand binding affects USP function that are implicit in the 
particular synthetic features of the various reporter assay systems. 
4.4. Implications for in vivo function of USP ligand binding pocket 
The present study has used the different approach of directly assessing whether there is a 
necessary in vivofunction of the ligand binding pocket of Drosophila USP. In the whole animal, 
a receptor expressed under its natural promoter is exposed to its putative natural endogenous 
ligands and its putative natural array of genomic targets. Our present report is the first to 
mutationally test specifically the ligand binding pocket of any full length RXR or USP protein in 
the whole animal environment. Our functional approach makes no a priori assumptions as to the 
identity of potential endogenous ligands and allows the test Drosophila USP to act upon the 
natural repertoire of putative USP target promoters in their normal tissues at normal 
developmental times. The outcome reported here of this functional approach, that yielded both 
morphogenetic and molecular marker phenotypes, supports an hypothesis that the USP ligand 
binding pocket has both a competence and a necessary function to bind ligand in order for 
normal morphogenetic larval to pupal development to proceed. 
The phenotypes of different point mutational disruptions of the USP ligand binding pocket all 
converged on severely suppressing the formation of a normal puparium. These finer mutations 
thus yielded a similar phenotype to previously reported conditional removal of the entire USP 
molecule during the 3rd instar [22]. This phenotype is different from that observed under 
conditions of either complete loss of JH reception during all three larval instars (i.e., null for both 
MET and GCE [1]; or of JH overreception (high concentration of methoprene or pyriproxifen in 
the diet [54]). Under the conditions of loss of JH reception (loss of JH receptor) for the entire 
period of larval development the larvae nevertheless reached attainment of a normal puparium. 
Under conditions of extreme JH overreception, those larvae that reached the 3rd instar also 
proceeded on to form a normal puparium [54]. Other than conditional removal of the entire USP 
molecule[22], i.e., removed all USP functions, there have been published little experimental data 
upon which to postulate what periods of larval development need specifically the function of 
USP ligand reception. Hence, we also used an experimental design that forced the test animals to 
rely upon the mutant USP ligand binding pocket from the outset of larval development, i.e., the 
design enabled detection of acute or cumulative effects of underreception of ligand binding 
during the entire period of larval development. Under these conditions, the mutational 
interference with normal reception of ligand by USP resulted in the failure to form a normal 
puparium at the end of the 3rd instar. 
The approach of disrupting a hormone/receptor axis by mutational interference with function of 
the specific receptor utilizes different tools than approaching it from the direction of interference 
with the production of ligand. From the direction of the receptor, the effect of ligand pocket 
mutation on the affinity for a specific postulated ligand can be carefully measured by kinetic 
techniques (e.g., Fig. 3, Fig. 5 and Fig. 6 here for methyl farnesoate and USP; Charles et 
al. [10] for JH III and GCE/MET). Approaches from the direction of disrupting ligand 
biosynthesis by corpora allatal cells of the ring gland have not yet reported what was resulting 
circulating titer of each of the three normally secreted methyl farnesoids during the three larval 
instars [42] and [55]. Also, suppression of HMGCR by RNAi driven in the corpora allatal cells 
yielded many larvae dying prior to the onset of metamorphosis [31], whereas in apoptotic ablation 
approaches, the death of the corpora allatal cells was not complete until sometime during the 3rd 
instar and the animals survived to the early pupal stage [42] and [55]. Hence, a more nuanced 
interpretation is required at this time on the phenotypic effects of suppressed methyl farnesoate 
production. In addition, it is also possible that a component of methyl farnesoate signaling during 
earlier instars becomes manifest at metamorphosis (e.g., as exogenous JH analog action during 
the 2nd instar becomes manifest at the pupal stage [54]). 
Upon then reaching the 3rd instar wandering stage, which itself is triggered by a pulse of 
20E [67], the mutant USP-expressing null larvae exhibited a normal level of transcript of both 
USP and EcR. We have shown that the mutational suppression in function of the USP ligand 
binding pocket did not allosterically cause the USP heterodimer partner EcR to become reduced 
in transducing ecdysteroid signaling, either (1) in a cultured cell assay, or (2) in vivo where the 
mutant USP-expressing null larvae underwent the first two larval molts in synchrony with 
normal siblings. Hence, the USP mutation itself did misconform USP in a way that in turn 
misconformed EcR into not responding to 20E. Remaining to be determined is whether 
endogenous ligand signaling through the USP pocket acts independent of 20E signaling. 
Alternatively, USP ligand may either modulate the 20E signaling coming through its partner, the 
EcR, or modulate particular interactions of 20E and JH III (or bisepoxyJH III). 
We have shown here that residues highly conserved in the ligand binding pocket of RXR and 
USP (Q288, N325) are necessary for high affinity binding of methyl farnesoate and enable a life-
necessary function ofDrosophila USP for metamorphic development. Q288 is conserved with a 
glutamine residue in vertebrate RXR that in cocrystal structure makes contact with the 
carboxylate end of the terpenoid 9-cis RA ( Fig. S3A and S3B). It has been proposed that the 
methyl ester of a terpenoid ligand could interact with Q288 inDrosophila USP [57]. Evolutionary 
considerations have generated the hypothesis that residues unique to dipteran USP that are even 
deeper into the pocket, such as N325 ( Fig. S3B), contribute to a hydrogen-bonding network that 
could interact with that methyl ester [57]. Supporting that proposition, we find here that disruption 
of larval to pupal metamorphosis occurs with mutation of either Q288 ( Fig. 5) or N325 ( Fig. 
6A). This metamorphosis-necessary N325 residue contributing to the ligand binding 
environment does not make contact with the “fortuitous” phospholipid that inserts at the pocket 
opening under crystal-formation conditions, further supporting that phospholipid is not the 
endogenous ligand whose signaling was disrupted by the mutation. The ability of TBT to 
exchange in equilibrium with methyl farnesoate, when the TBT semicovalent attachment site is a 
cysteine near to the pocket opening [43], further confirms the functional performance of both the 
proximal and distal ends of the Drosophila USP ligand binding pocket under our conditions here. 
4.5. Evolutionary implications 
Methyl farnesoate is considered as the primary circulating hormone regulating a variety of 
morphogenetic events in crustacean development [41]. It has been suggested that in the evolution 
of Insecta, the insects have retained biosynthetic secretion of methyl farnesoate in addition to 
acquisition of a new hormone axis centered on the epoxidation product of methyl farnesoate, i.e., 
juvenile hormone [13] and [30]. We have reported here that methyl farnesoate is in circulation in a 
mecopteran (Drosophila) at a level favorably comparable with its binding affinity to USP, and 
that in vivo function of USP is disrupted by mutations to the ligand binding pocket that weaken 
the pocket’s affinity for methyl farnesoate. Our detection of circulating methyl farnesoate, in 
addition to JH III, not just in Drosophila, but also in late final instar mosquito larvae (Fig. S6), 
indicates that the findings reported here may also relate to dipteran vectors of disease. 
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Appendix A. Supplementary data 
Supplementary data 1.  Available online at http://dx.doi.org/10.1016/j.ygcen.2012.11.009  
Purification of recombinant, Q288A mutant ultraspiracle of Drosophila melanogaster. The 
receptor coding sequence in a pET32EK (Novagen) was induced to be expressed in AD494 
bacteria by addition of IPTG and grown for several hours at 30 °C (Panel A, “IPTG”). After 
sonication and centrifugal precipitation of the insoluble bacterial debris, the supernatant was 
added to a nickel resin column. The recombinant protein, that includes an N-terminal His-STAG 
fusion segment, was retained on the column and did not appear either in the portion of the 
sample that flowed through (“Flow”), nor was it washed from the column by 10 mM imidazole 
(“Wash”). The retained protein was then eluted and concentrated to ca. 1 ml volume under 
nitrogen pressure with through an Amicon 30 kDa pore size membrane (“Elute Conc.”). The 
concentrated sample was then passed through a Superdex 200 size exclusion column and 
fractions obtained, each containing the purified protein (Panel B). The purified protein migrates 
on SDS–PAGE slightly slower than pre-stained bovine serum albumin. The fractions containing 
the purified protein were combined and diluted to a final receptor concentration of 0.7–1 μM 
(SDS–PAGE of the combined fractions protein is shown in Fig. 3 and S2). Purification of the 
wild type USP behaved in the same way as shown here for the Q288A mutant. 
Supplementary data 2.  Available online at http://dx.doi.org/10.1016/j.ygcen.2012.11.009  
Stability of wild type and mutant Q288A USP during the fluorescence binding assay. The 
purified receptor was diluted to 1 μM final concentration and held overnight at 4 °C. Then, 
1.7 ml of that receptor preparation was dispensed into a quartz cuvette, and 1.7 ml of methyl 
farnesoate (in ethanol) was added to a final concentration (in this example, wt USP has 0.8 μM 
ligand; Q288A has 5 μM ligand). Shown is the % suppression in fluorescence at 5 min intervals 
after the addition (immediately after time 0) of methyl farnesoate. After 45 min, the average of 
the nine measured values for each concentration was determined and used as a datum in the 
calculation of Kd values shown in Fig. 3. Shown on the right in this figure is an aliquot of the 
given receptor preparation that was taken at the completion of the binding assay, and it shows no 
significant degradation for either wt USP or Q288A USP. Hence, the abrupt decrease in 
fluorescence seen upon ligand addition, and then the stable maintenance of suppressed 
fluorescence, is not due to degradation of the receptor during the 45 min course of the binding 
assay. Similar stability was demonstrated for the N325A and Q288 L366A mutants (not shown). 
Supplementary data 3.  Available online at http://dx.doi.org/10.1016/j.ygcen.2012.11.009  
Comparison of ion chromatograms of base peaks (diagnostic ions used for quantification) of an 
extract of 1.5 μl of hemolymph obtained from 3rd instar larvae, with the ion chromatograms of 
an equal mixture (25 pg each) of synthetic MF (m/z = 251 (m+1); 19–19.5 min), JH III 
(m/z = 235 (m+1−CH3OH); 19.5–20.5 min), and JH IIIB (m/z = 283 (m + 1); 20.5–22.0 min). 
Supplementary data 4.  Available online at http://dx.doi.org/10.1016/j.ygcen.2012.11.009  
Comparison of residues in the ligand binding pocket of Drosophila melanogaster ultraspiracle 
(USP), with those residues of the human retinoid acid receptor (hRXR) that make contact with 
the carboxyl end of 9-cis retinoic acid in crystal structure (USP, [9]; PDB #1hg4; hRXR, [14], PDB 
#1fby). On the left in Panels A and B, are global views of the respective ligand binding domains, 
as viewed with Cn3D software. On the right in Panels A and B are close-up views of the residues 
in the ‘deep end’ of the ligand binding pocket. In the hRXR structure, the side chain of Q288 
makes a hydrogen bond with a carboxylate oxygen of ligand 9-cis RA (ligand terpenoid 
backbone in grey; oxygen atoms in red). The corresponding pocket space (dashed orange circle) 
is shown for in Panel B for USP. In that space, the glutamine residue is conserved as Q288, and 
there is also present N325 that is located even further back into the pocket. A phospholipid 
(shown in grey, with grey arrow) that is seen in crystal structure preparations of USP does not 
extend sufficiently into that space to make contact with N325. In a theoretical docking study 
Sasorith et al. [52] inferred that Q288 and N325 contribute to an intricate hydrogen bonding 
network that would preferably bind a methyl ester over a charged free carboxylate, 
approximately in the position diagrammed in Panel C (adapted from Sasorith et al. [52]). In the 
present study, we have performed an alanine mutational analysis of Q288 and N325 in D. 
melanogaster USP. Also shown here are W318 (USP) and W305 (hRXR). In crystal structure, 
W305 of hRXR is close to the bound 9-cis RA, which is a basis of an equilibrium fluorescence 
quenching assay for binding of 9-cis RA [14]. We have shown that this fluorescence binding assay 
can also be used to measure the binding affinity of methyl farnesoate and related structures to 
USP [31]. The red arrow in the global USP view in B is the position of the cysteine residue at 
which TBT binds in vertebrate RXR [40]. 
Supplementary data 5.  Available online at http://dx.doi.org/10.1016/j.ygcen.2012.11.009  
Fluorescence exhibited by the wild type and two mutants of USP in the presence of the indicated 
ligand, relative to the fluorescence in the presence of just the EtOH carrier. The binding of 
methyl farnesoate (MF) to wild type USP (fluorescence suppressed to 90%) is significantly 
weakened by the mutations to the ligand binding pocket (t, p < 0.01 each). At the same 
concentration of ligand, there is significantly less binding of juvenile hormone III (JH III) with 
the wild type USP (t, p < 0.01). The mutations of the ligand binding pocket did not cause the 
mutant receptor to exhibit with JH III the same fluorescence effect that occurs with MF binding 
to wild type USP (t, p < 0.01 each). At this ligand concentration, farnesol (FO) was 
indistinguishable from EtOH (t, p > 0.05). 
Supplementary data 6.  Available online at http://dx.doi.org/10.1016/j.ygcen.2012.11.009  
qPCR expression analysis of the pupal cuticle gene Edg84 in normal vs. mutant USP, relative to 
the gene for ribosomal protein RPl32. Early Puparia = 0–3 h after white puparium formation for 
normal animals; Near Pupation = at or within several hours of pupal head eversion for normal 
animals. The stages for larvae expressing only mutant USP were selected by the corresponding 
time since the wandering larva became quiescent. For both normal and mutant USP animals, the 
expression increased more than 100× at the latter stage over the earlier stage (t, p < 0.01 each). 
Supplementary data 7.  Available online at http://dx.doi.org/10.1016/j.ygcen.2012.11.009  
Chemical ionization (isobutane) GC–MS analysis , using limited ion monitoring, of synthetic and 
natural MF from late third instar A. aegypti larvae just prior to pupation. Panel A: ion 
chromatogram (m/z = 251, m+1) of synthetic MF. Panel B: ion chromatogram (m/z = 251, m+1) 
of natural MF; Panel C: mass spectrum of diagnostic ions used to document and quantify MF 
(m/z = 251, m+1;m/z = 219, m+1−CH3OH; m/z = 191, m+1−CH3OH–CO). 
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